A similar induced activation of AKT leading to a resistance of rapamycin treatment has been observed in human lung cancer cells and human rhabdomyosarcoma cell lines and in rodent cells overexpressing insulin-like growth factor (IGF) II (Sun et al., 2005; Wan et al., 2007). This evidence concerns the gene AKT1 and lung cancer.